<DOC>
	<DOCNO>NCT01055652</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics dapagliflozin administer alone combination voglibose Japanese patient type 2 diabetes assessment AUC Cmax dapagliflozin</brief_summary>
	<brief_title>Drug-drug Interaction Study Dapagliflozin With Voglibose Japanese Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<criteria>Already voglibose treatment steady dosage least 8 week Provision inform consent prior study specific procedure Diagnosed type 2 diabetes Having clinically relevant medical history concurrent disease cardiovascular disease , renal disease , retinopathy , hepatic disease haematological disease . The investigator ( ) judge Subject participate study accord screen test medical history .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 1</keyword>
	<keyword>safety</keyword>
	<keyword>dapagliflozin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-drug Interaction</keyword>
	<keyword>voglibose</keyword>
</DOC>